Zai Lab Limited released its 2025 “Trust for Life” report, highlighting material progress toward its three headline sustainability and growth objectives:

1. Patient reach accelerates • An additional 286,000 patients accessed Zai Lab medicines in 2025, taking cumulative treated patients to 844,000 since 2019; the company reiterated its goal of surpassing 1 million patients by 2030. • Patient Access Programmes added 1,663 financially challenged patients during the year; total beneficiaries since inception stand at 7,447. • Five of the group’s eight marketed products—Zejula, Qinlock, Nuzyra, Vyvgart and Augtyro—are now on China’s National Reimbursement Drug List, broadening affordability.

2. Pipeline expansion and commercial milestones • Lead asset zocilurtatug pelitecan (DLL3-targeting ADC, “zoci”) moved from IND to global Phase 3 within two years; three registration-enabling studies are scheduled to commence by end-2025, supporting a planned first global launch in 2028. • Additional programmes advancing include ZL-1503 (IL-13/IL-31Rα bispecific, atopic dermatitis), ZL-6201 (LRRC15 ADC, sarcoma), ZL-1222 (PD-1/IL-12 immunocytokine) and ZL-1311 (MUC17/CD3 T-cell engager). • In China, the National Medical Products Administration approved KarXT for adult schizophrenia in December 2025; commercial launch is targeted for Q2 2026. • Preparations are under way for potential approvals of TIVDAK in cervical cancer and TTFields in pancreatic cancer.

3. Human capital and governance highlights • Women constitute 59 % of the workforce; female representation is 54 % across all management roles and 53 % in STEM-related management. Base-pay gender equity is maintained at every level. • A new mentoring scheme enrolled 14 high-potential employees, while average annual training hours reached 26.2 per employee. • Enterprise Risk Management reviews and healthcare-compliance assessments were completed; new Commercial and R&D Compliance Committees were formed for Greater China operations.

4. Environmental footprint • Total 2025 greenhouse-gas emissions were 65,069 tCO₂e; although absolute emissions rose versus 2024, intensity fell to 0.14 per US-dollar of revenue, reflecting operational efficiency gains. • Enhanced data collection incorporated chilled-water and steam usage for the first time, improving Scope 2 accuracy.

Financial context Revenue grew to USD 460 million in 2025, up from USD 399 million in 2024, underpinning continued investment in R&D and access programmes.

Outlook Management reaffirmed commitment to reach one million patients by 2030, maintain gender-pay parity and execute annual top-tier risk-mitigation plans while driving the pipeline toward at least 15 commercialised products by the end of the decade.